Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade C 23.78 1.80% 0.42
NCNA closed up 1.8 percent on Thursday, September 20, 2018, on 1.15 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical NCNA trend table...

Date Alert Name Type % Chg
Sep 20 Crossed Above 50 DMA Bullish 0.00%
Sep 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 20 Outside Day Range Expansion 0.00%
Sep 19 Fell Below 50 DMA Bearish 1.80%
Sep 19 180 Bearish Setup Bearish Swing Setup 1.80%
Sep 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.80%
Sep 19 Narrow Range Bar Range Contraction 1.80%
Sep 19 Outside Day Range Expansion 1.80%
Sep 18 50 DMA Support Bullish -0.59%
Sep 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.59%

Older signals for NCNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Is NCNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.0
52 Week Low 9.32
Average Volume 31,811
200-Day Moving Average 21.371
50-Day Moving Average 23.5819
20-Day Moving Average 24.2083
10-Day Moving Average 23.5665
Average True Range 1.5103
ADX 11.32
+DI 13.7469
-DI 17.6366
Chandelier Exit (Long, 3 ATRs ) 25.5691
Chandelier Exit (Short, 3 ATRs ) 26.6109
Upper Bollinger Band 26.413
Lower Bollinger Band 22.0036
Percent B (%b) 0.4
BandWidth 18.214414
MACD Line -0.1138
MACD Signal Line -0.0376
MACD Histogram -0.0763
Fundamentals Value
Market Cap 756.47 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -59.45
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.16
Resistance 3 (R3) 25.10 24.57 24.93
Resistance 2 (R2) 24.57 24.22 24.61 24.85
Resistance 1 (R1) 24.18 24.00 24.38 24.24 24.78
Pivot Point 23.65 23.65 23.75 23.69 23.65
Support 1 (S1) 23.26 23.30 23.46 23.32 22.78
Support 2 (S2) 22.73 23.08 22.77 22.71
Support 3 (S3) 22.34 22.73 22.63
Support 4 (S4) 22.40